Das Prüfprogramm für das Leitprojekt HDP-101 zeigt unverändert Sicherheit und gute Verträglichkeit. Die 4. Dosiseskalations-Gruppe war im Q3/23 recht zügig abgeschlossen worden; nun werden Patienten für die 5. Kohorte (100 g/kg) rekrutiert. Ein Patient, der seit 9 Monaten kein Fortschreiten der Krankheit (stable disease) zeigt, erhielt zwölf Dosen HDP-101 Monotherapie und erhält nun die Möglichkeit der nächsthöheren Dosis (80 µg/kg). Der Übergang in die Phase 2a mit HDP-101 könnte u.E. im H1/24...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
A director at Mirati Therapeutics Inc sold 2,546 shares at 44.660USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
The independent financial analyst theScreener just awarded an improved star rating to MIRATI THERAP (CA), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date March 4, 2022, ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.